<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926898</url>
  </required_header>
  <id_info>
    <org_study_id>ZX008-1504</org_study_id>
    <nct_id>NCT02926898</nct_id>
  </id_info>
  <brief_title>A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥2 Years Old and Young Adults With Dravet Syndrome</brief_title>
  <official_title>A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care , Followed by a Randomized, Double-blind, Placebo-controlled Parallel Group Evaluation of the Efficacy, Safety, and Tolerability of ZX008 as Adjunctive Antiepileptic Therapy to Stiripentol Treatment in Children and Young Adults With Dravet Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zogenix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety, tolerability and efficacy of a
      single dose of ZX008 (Fenfluramine Hydrochloride) when added to standard of care and when
      added to Adjunctive Antiepleptic therapy to Stiripentol treatment in children and young
      adults with Dravet Syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, two-cohort trial to assess the pharmacokinetic and safety profile of a
      single dose of ZX008 (fenfluramine hydrochloride) oral solution when added to Dravet syndrome
      treatment regimen containing VPA and CLB, with or without STP (Cohort 1), followed by a
      randomized, double-blind, placebo-controlled parallel group evaluation of the efficacy,
      safety, and tolerability of ZX008 as adjunctive therapy for seizures in children and young
      adults with Dravet syndrome (Cohort 2). Cohort 2 will not be dosed until the PK and safety
      data from Cohort 1 have been collected and evaluated. The PK and safety data from Cohort 1
      will determine the dose of ZX008 to be used in Cohort 2.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in frequency of convulsive seizures in subjects receiving ZX008 0.2 mg/kg/day as adjunctive therapy compared to placebo</measure>
    <time_frame>Time between 6-week baseline assessment period and 12 week treatment and maintenance period</time_frame>
    <description>Parent/caregiver seizure diary record will be used to assess frequency, type and duration of seizure activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in frequency of convulsive seizures in subjects receiving ZX008 0.4 mg/kg/day as adjunctive therapy compared to placebo</measure>
    <time_frame>Time between 6-week baseline assessment period and 12 week treatment and maintenance period</time_frame>
    <description>Parent/caregiver seizure diary record will be used to assess frequency, type and duration of seizure activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a ≥40% or ≥50% reduction from baseline in convulsive seizure frequency and longest seizure-free interval in subjects receiving ZX008 0.2 and 0.4 mg/kg/day as adjunctive therapy compared to placebo</measure>
    <time_frame>Time between 6-week baseline assessment period and combined 12 week treatment and maintenance period</time_frame>
    <description>Parent/caregiver seizure diary record will be used to assess frequency, type and duration of seizure activity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and tolerability of ZX008 0.2 and 0.4 mg/kg/day as adjunctive therapy compared to placebo</measure>
    <time_frame>Week 1 through Week 12</time_frame>
    <description>Safety and tolerability evaluated by reported adverse events, laboratory parameters, physical and neurological examination, vital signs, electrocardiograms, echocardiograms, and body weight. (Cognitive function will be assessed using age-appropriate versions of the Brief Rating Inventory of Executive Function [BRIEF].)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dravet Syndrome</condition>
  <arm_group>
    <arm_group_label>ZX008 - 0.2 mg/kg/day - Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZX008 0.2 mg/kg/day is supplied as an oral solution and will be administered twice a day (BID) in equally divided doses with food.
Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZX008 - 0.4 mg/kg/day - Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZX008 - 0.4 mg/kg/day is supplied as an oral solution and will be administered twice a day (BID) in equally divided doses with food.
Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZX008 - 20 mg/day maximum - Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZX008 - 20 mg/day maximum dose is supplied as an oral solution administered twice a day day (BID) in equally divided doses with food. Dose to be determined based on based on Cohort 1 .
Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo - Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered twice a day (BID) in equally divided doses with food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZX008 - 0.2 mg/kg/day</intervention_name>
    <description>ZX008 - 0.2 mg/kg/day ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/ mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.</description>
    <arm_group_label>ZX008 - 0.2 mg/kg/day - Cohort 1</arm_group_label>
    <other_name>Cohort 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZX008 - 0.4 mg/kg/day</intervention_name>
    <description>ZX008 - 0.4 mg/kg/day ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/ mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.</description>
    <arm_group_label>ZX008 - 0.4 mg/kg/day - Cohort 1</arm_group_label>
    <other_name>Cohort 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZX008 - 20 mg/day maximum dose</intervention_name>
    <description>ZX008 - 20 mg/day maximum dose ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and</description>
    <arm_group_label>ZX008 - 20 mg/day maximum - Cohort 2</arm_group_label>
    <other_name>Cohort 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>ZX008 Matching Placebo</description>
    <arm_group_label>Matching Placebo - Cohort 2</arm_group_label>
    <other_name>Cohort 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subject must be male or non-pregnant, non-lactating female, age 2 to 18 years
             (inclusive)

          -  Subject must have documented medical history to support a clinical diagnosis of Dravet
             syndrome, where convulsive seizures are not completely controlled by current
             antiepileptic drugs.

          -  Subject must be receiving a therapeutically relevant and stable dose of CLB, VP, and
             STP for at least 4 weeks prior to screening and are expected to remain stable
             throughout the study (Cohort 2 only).

          -  Subject must be receiving a stable dose of CLB and VPA, administered twice daily, to
             be eligible for Dose Regimen 1 and 2 or subject must be receiving a stable dose of
             CLB, VPA, and STP, administered twice daily, to be eligible for Dose Regimen 3 (Cohort
             1 only).

        Key Exclusion Criteria:

          -  Subject has a known hypersensitivity to fenfluramine or any of the excipients in the
             study medication.

          -  Subject has pulmonary arterial hypertension.

          -  Subject has a current or past history of cardiovascular or cerebrovascular disease,
             such as cardiac valvulopathy, myocardial infarction or stroke.

          -  Subject has a current or recent history of anorexia nervosa, bulimia, or depression
             within the prior year that required medical treatment or psychological treatment for a
             duration greater than 1 month.

          -  Subject has a current or past history of glaucoma.

          -  Subject is receiving concomitant therapy with: centrally-acting anorectic agents;
             monoamine-oxidase inhibitors; any centrally-acting compound with clinically
             appreciable amount of serotonin agonist or antagonist properties, including serotonin
             re-uptake inhibition; triptans, atomoxetine, or other centrally-acting noradrenergic
             agonist; cyproheptadine, and/or CYP 2D6/3A4/2B6 inhibitors/substrates.

          -  Subject is currently taking carbamazepine, oxcarbamazepine, eslicarbazepine,
             phenobarbital, or phenytoin, or has taken any of these within the past 30 days, as
             maintenance therapy.

          -  Subject has a positive result on urine THC Panel or whole blood CBD at the Screening
             Visit.

          -  Subject has a clinically significant condition, or has had clinically relevant
             symptoms or a clinically significant illness in the 4 weeks prior to the Screening
             Visit, other than epilepsy, that would negatively impact study participation,
             collection of study data, or pose a risk to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children'S Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert Lurie Children'S Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children'S Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Amiens Picardie Service de Neurologie Pediatrique</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU DE BORDEAUX Service De Pédiatrie Médicale</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU LILLE Centre Hospitalier Régional Universitaire De Lille 2</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÔPITAL FEMME-MÈRE-ENFANT Hôpital Femme-mère-enfant Service De Neurologie Pédiatrique</name>
      <address>
        <city>Lyon</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone, Service de Neurologie Pédiatrique</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENTRE REFERENT DES EPILEPSIES Hopital De Hautpierre</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>F-67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÔPITAL DES ENFANTS Pédiatrie</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Denfants Chru de Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Mara Ggmbh, Epilepsiezentrum Bethel</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Klinik Für Neuropädiatrie</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kleinwachau Sächsisches Epilepsiezentrum Radeberg Gemeinnützige Gmbh</name>
      <address>
        <city>Radeberg</city>
        <zip>1454</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kempenhaeghe</name>
      <address>
        <city>Heeze</city>
        <zip>5590 Ab</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stichting Epilepsie Instellingen Nederland</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 BV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional Primera Planta Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Neurosciences Queens Elizabeth University</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children'S Nhs Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evelina Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormonnd Street Hospital For Children Nhs Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seizure</keyword>
  <keyword>tonic clonic</keyword>
  <keyword>epilepsy</keyword>
  <keyword>myoclonic</keyword>
  <keyword>encephalopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Epilepsies, Myoclonic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Fenfluramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

